Mereo BioPharma (MREO) Accumulated Depreciation (2022 - 2026)

Mereo BioPharma (MREO) has reported Accumulated Depreciation for 5 consecutive years, with $978000.0 the latest figure, recorded in Q1 2026.

• Quarterly Accumulated Depreciation fell 3.74% year-over-year to $978000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $978000.0 (down 3.74% YoY) and the FY2025 annual result came in at $1.1 million, up 14.33% from the prior year.
• Accumulated Depreciation slipped to $978000.0 in Q1 2026 per MREO's latest filing, from $1.1 million in the prior quarter.
• Over the last five years, Accumulated Depreciation for MREO reached as high as $1.1 million in Q2 2025 and fell as low as $736000.0 in Q4 2022.
• A 5-year average of $945272.7 and a median of $964000.0 in 2024 frame the typical range for Accumulated Depreciation.
• Annual changes were most pronounced in 2025 — Accumulated Depreciation rose 26.57% — and 2026, when it retreated 3.74%.
• Year by year, Accumulated Depreciation stood at $736000.0 in 2022, then gained by 8.7% to $800000.0 in 2023, then gained by 18.62% to $949000.0 in 2024, then increased by 14.33% to $1.1 million in 2025, then decreased by 9.86% to $978000.0 in 2026.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $978000.0, $1.1 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.